Enhanced drug penetration into tumor tissue

The entity "Enhanced drug penetration into tumor tissue" is not a molecule, receptor, or singular macromolecular target but rather a therapeutic objective or pharmacological property. It refers to strategies or processes intended to increase the ability of drugs to reach all tumor cells by overcoming physical and physiological barriers within solid tumors. Thus, it does not represent a canonical molecular target itself. "Enhanced drug penetration into tumor tissue" refers to approaches, modalities, or treatments designed to increase the delivery and distribution of therapeutic drugs within solid tumors. Drug penetration in tumor tissue is limited by factors such as abnormal and poorly organized tumor vasculature, high interstitial fluid pressure, dense stroma, and heterogeneous tumor cell uptake[1][2][3]. Drug molecules must traverse the vascular endothelium, diffuse (or convect) through the tumor extracellular matrix, and avoid sequestration, metabolism, or export before reaching all malignant cells at effective concentrations[1][2]. Insufficient penetration is a leading cause of resistance to chemotherapy and other anticancer agents in solid tumors, prompting research into formulation strategies (e.g., liposomal drugs, nanoparticles), physical methods (e.g., hyperthermia, ultrasound), and drug property optimization to improve tissue distribution[1][2][3]. "Enhanced drug penetration" is therefore a treatment goal, not a discrete molecular or receptor target.

Other names

Tumor drug penetrationDrug penetration into tumor tissueDrug distribution in tumor